Group 1 - The Chemours Company (NYSE:CC) is considered chronically undervalued, despite concerns regarding "forever chemicals" which are believed to be behind the company [1] - Chemours delivers specialty chemicals across various industries, including refrigerants, pigments, resins, coatings, and advanced materials for applications in electronics, packaging, energy, transportation, and medical fields [1] - Mizuho analyst John Roberts raised Chemours' price target to $19 from $16 while maintaining an Outperform rating, citing favorable settlement progress regarding per- and polyfluoroalkyl substances and stronger market valuations [1]